TrialPath
Recruiting

A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis

NCT05744466 · Bristol-Myers Squibb
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
A Real-world, Prospective, Observational Study of the Comparative Effectiveness of Deucravacitinib Versus Apremilast in Adults With Plaque Psoriasis - North American Region
About this study
The purpose of this study is to understand the comparative effectiveness of deucravacitinib versus apremilast in adults with plaque psoriasis.
Eligibility criteria
Inclusion Criteria: * Have been diagnosed with plaque psoriasis by a dermatologist * Newly initiating an eligible medication for enrollment (i.e., deucravacitinib, apremilast) * Actively enrolled in the CorEvitas Psoriasis Registry and have documented consent to allow copies of information from the registry be used for research purposes Exclusion Criteria: * Participation (current or planned) in an interventional clinical trial (does not include observational registry or study) * Restart of treatments with the study eligible therapies previously received at any time during the participants' treatment history
Study design
Enrollment target: 1500 participants
Age groups: adult, older_adult
Timeline
Starts: 2022-09-30
Estimated completion: 2027-12-10
Last updated: 2024-07-23
Interventions
Drug: DeucravacitinibDrug: Apremilast
Primary outcomes
  • • Change in body surface area (BSA) (At baseline and every 6 months up to 60 months or treatment discontinuation)
  • • Investigator global assessment (IGA) response 0/1 (Up to 60 months)
  • • Dermatology life quality index (DLQI) response 0/1 (Up to 60 months)
Sponsor
Bristol-Myers Squibb · industry
Contacts & investigators
ContactBMS Study Connect Contact Center www.BMSStudyConnect.com · contact · Clinical.Trials@bms.com · 855-907-3286
ContactFirst line of the email MUST contain the NCT# and Site #. · contact
InvestigatorBristol-Myers Squibb · study_director, Bristol-Myers Squibb
All locations (1)
Local InstitutionRecruiting
Waltham, Massachusetts, United States
A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis · TrialPath